BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
4 DSLR Cameras for Amateurs in 2024 - 25 Critical Rules For Business Regulation Chiefs
- 3The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- 4‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- 5Cheetos and Doritos to launch new versions without artificial dyes
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
- Portable Installment Answers for Independent ventures
- I watched more than 500 new movies this year. These are the 25 best ones.
- Extreme Manual for Purchasing Your Next Truck
- My Excursion to a Better Way of life: Health Experiences
- Grasping Various Kinds of Local misdemeanors
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- Pick Your Number one sort of blossom
